2 recruiting, 1 active not recruiting, 1 completed, 1 terminated. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Recruiting 2, Terminated 1 |
| Phase 2 | 3 | Active not recruiting 1, Completed 1, Recruiting 1 |
Follow Locally Advanced Skin Squamous Cell Carcinoma: new trials by email Literature Review of Locally Advanced Skin Squamous Cell Carcinoma trials Research Report on Locally Advanced Skin Squamous Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer Cemiplimab, Radiotherapy - Cutaneous Squamous Cell Carcinoma, Skin Cancer | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 34 | 2022-10-06 | 2026-05-15 |
| Radiotherapy in Combination With Atezolizumab in Locally Advanced Borderline Resectable or Unresectable Cutaneous SCC Atezolizumab, Stereotactic Body Radiation Therapy - Locally Advanced Skin Squamous Cell Carcinoma, Resectable Skin Squamous Cell Carcinoma | Phase 1 | Recruiting | City of Hope Medical Center | 12 | 2022-04-19 | 2026-01-28 |
| Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 138 | 2022-03-31 | 2026-08-20 |
| Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin Panitumumab, Talimogene Laherparepvec - Locally Advanced Skin Squamous Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma | Phase 1 | Terminated | Rutgers, The State University of New Jersey | 5 | 2020-01-31 | 2026-01-23 |
| Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors Atezolizumab, Cobimetinib - Skin Squamous Cell Carcinoma, Appendix Adenocarcinoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 49 | 2017-04-07 | 2025-05-28 |
Neoplasm Metastasis (2) · Adenocarcinoma, Mucinous (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Lobular (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Carcinoma, Squamous Cell (1) · Carcinoma, Transitional Cell (1) · Carcinosarcoma (1) · Endometrial Neoplasms (1) · Lung Neoplasms (1) · Melanoma (1) · Neoplasms (1) · Skin Neoplasms (1)
Carcinoma (3) · Neoplasms by Histologic Type (3) · Neoplasms, Glandular and Epithelial (3) · Adenocarcinoma (2) · Neoplasms (2) · Neoplasms by Site (2) · Neoplastic Processes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Skin Diseases (2) · Skin and Connective Tissue Diseases (2) · Breast Diseases (1) · Breast Neoplasms (1) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1)
atezolizumab (2) · Biopsy (1) · Colony-Stimulating Factors (1) · Cyclophosphamide (1) · Immunoglobulin G (1) · Magnetic Resonance Spectroscopy (1) · Panitumumab (1) · Radiosurgery (1) · Radiotherapy (1) · Specimen Handling (1) · X-Rays (1) · cemiplimab (1) · cobimetinib (1) · pembrolizumab (1) · sargramostim (1)
City of Hope Medical Center (1) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · Memorial Sloan Kettering Cancer Center (1) · Rutgers, The State University of New Jersey (1)
United States (5)
Adam C Berger, MD, FACS (1) · Arya Amini (1) · Christopher Barker, MD (1) · Kanwal P Raghav (1) · Yanyan Lou, MD, PhD (1)
P30CA033572 (1), P30CA072720 (1)